Antibacterial biaromatic derivatives
View Patent ↗The invention relates to antibacterial compounds of formula I and salts thereof and methods of treating bacterial infection using the compounds.
1. A compound of formula I
wherein
R represents H, cyano, (C 1 -C 3 )alkoxy, cyanomethoxy, (C 3 -C 6 )cycloalkylmethoxy, hydroxy(C 2 -C 4 )alkoxy, (C 1 -C 3 )alkoxy-(C 2 -C 3 )alkoxy, (C 1 -C 4 )alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (1-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-1-yl or (3,4-dihydroxycyclopentyl)methoxy;
U 1 represents N or CR 1 , U 2 represents N or CR 2 , U 3 represents N or CR 3 and U 4 represents N or CR 4 , wherein at most three of U 1 , U 2 , U 3 and U 4 can represent N at the same time;
V 1 represents N or CR 5 , V 2 represents N or CR 6 , V 3 represents N or CR 7 and V 4 represents N or CH, wherein at most two of V 1 , V 2 , V 3 and V 4 can represent N at the same time;
R 1 represents H, cyano, hydroxy or (C 1 -C 3 )alkoxy;
R 2 represents H, hydroxy or (C 1 -C 3 )alkoxy;
R 3 represents H, cyano, hydroxy, (C 1 -C 3 )alkoxy or carboxamido;
R 4 represents H, cyano, hydroxy or (C 1 -C 3 )alkoxy;
R 5 represents H, hydroxy or halogen;
R 6 represents H, hydroxy or halogen;
R 7 represents H;
the dotted line “-----” represents a bond or is absent;
W represents CH or N when the dotted line “-----” is a bond, or W represents CH 2 when the dotted line “-----” is absent;
X represents CH or N; and
Q represents O or S;
or a salt of the compound.
2. The compound of formula I according to claim 1 ,
wherein
R represents H, (C 1 -C 3 )alkoxy or cyano;
V 1 represents N or CR 5 , V 2 represents N or CR 6 and V 3 represents N or CR 7 , it being understood that at most one of V 1 , V 2 and V 3 can represent N at the same time;
V 4 represents CH
R 1 represents H, hydroxy or cyano;
R 3 represents H, hydroxy, (C 1 -C 3 )alkoxy or carboxamido;
R 4 represents H;
R 5 represents H or halogen; and
R 6 represents H or halogen;
or a salt of the compound.
3. The compound of formula I according to claim 1 , wherein the dotted line “-----” is absent and W represents CH 2 ;
or a salt of the compound.
4. The compound of formula I according to claim 1 , wherein the dotted line “-----” represents a bond;
or a salt of the compound.
5. The compound of formula I according to claim 1 , wherein X represents CH and Q represents S or X represents N and Q represents O;
or a salt of the compound.
6. The compound of formula I according to claim 5 , wherein X represents CH and Q represents S;
or a salt of the compound.
7. The compound of formula I according to claim 5 , wherein X represents N and Q represents O;
or a salt of the compound.
8. The compound of formula I according to claim 1 , wherein:
the dotted line “-----” is absent and W represents CH 2 or the dotted line “-----” is a bond and W represents CH;
R represents methoxy or cyano;
U 2 , U 3 or U 4 each represent CH and U 1 represents CR 1 wherein R 1 represents H or hydroxy, or U 1 represents N, U 2 represents CR 2 , U 3 represents CR 3 and U 4 represents CR 4 , or U 1 represents CR 1 , U 2 represents N, U 3 represents CR 3 and U 4 represents CR 4 , or U 1 represents CR 1 , U 2 represents CR 2 , U 3 represents N and U 4 represents CR 4 , or U 1 represents CR 1 , U 2 represents CR 2 , U 3 represents CR 3 and U 4 represents N, or U 1 and U 2 represent N and U 3 and U 4 represent CH; and
V 1 represents CH or N and V 2 and V 3 each represent CH;
or a salt of the compound.
9. The compound of formula I according to claim 1 , wherein:
R represents cyano or methoxy;
each of U 1 , U 2 , U 3 , U 4 , V 1 , V 2 , V 3 and V 4 represents CH, or U 1 represents N, V 1 represents CR 5 wherein R 5 is hydroxy, and each of U 2 , U 3 , U 4 , V 2 , V 3 and V 4 represents CH, or U 4 represents N, V 1 represents CR 5 wherein R 5 is hydroxy, and each of U 1 , U 2 , U 3 , V 2 , V 3 and V 4 represents CH, or U 4 represents N, V 2 represents CR 6 wherein R 6 is hydroxy, and each of U 1 , U 2 , U 3 , V 1 , V 3 and V 4 represents CH, or each of U 1 and U 2 represents N, V 1 represents CR 5 wherein R 5 is H or hydroxy, V 1 represents CR 5 and each of U 3 , U 4 , V 2 , V 3 and V 4 represents CH, or V 1 represents N, U 1 represents CR 1 wherein R 1 is hydroxy and each of U 2 , U 3 , U 4 , V 2 , V 3 and V 4 represents CH, or each of U 1 , U 2 and V 3 represents N and each of U 3 , U 4 , V 1 , V 2 and V 4 represents CH;
the dotted line “-----” represents a bond or is absent;
W represents CH when the dotted line “-----” is a bond, or W represents CH 2 when the dotted line “-----” is absent;
X represents CH or N; and
Q represents O or S;
or a salt of the compound.
10. The compound of formula I according to claim 1 , wherein the compound is:
6-((R)-5-{2-[(3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
2-methoxy-6-[3-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-isonicotinonitrile;
3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-((S)-5-{2-[(3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3′-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-((R)-5-{2-[(4′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[(4′-hydroxy-3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
5-methoxy-3′-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-2-carbonitrile;
5-methoxy-3′-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-((R)-5-{2-[(3′-hydroxy-5′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[(6-fluoro-3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[(2-fluoro-3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(5-methoxy-pyridin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(4-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(6-methoxy-pyridin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
5-[3-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-nicotinonitrile;
6-[3-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
6-hydroxy-5-[3-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-nicotinonitrile;
6-[(R)-5-(2-{[6-(3-methoxy-phenyl)-pyridin-2-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one;
6-[(R)-5-(2-{[4-(3-methoxy-phenyl)-pyridin-2-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[(6′-methoxy-[2,2]bipyridinyl-6-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(4-methoxy-pyrimidin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(6-methoxy-pyrimidin-4-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(6-methoxy-pyrazin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(2,6-dimethoxy-pyrimidin-4-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(4,6-dimethoxy-pyrimidin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
3-methoxy-3′-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-4-carboxylic acid amide;
6-((R)-5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((R)-5-{2-[3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
5-methoxy-3′-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-2-carbonitrile;
3′-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-(5-{2-[(3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-(5-{2-[3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3′-({2-[2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-2,3-dihydro-oxazol-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
5-methoxy-3′-({2-[2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-2,3-dihydro-oxazol-5-yl]-ethylamino}-methyl)-biphenyl-2-carbonitrile;
4-hydroxy-3-[4-({2-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-pyridin-2-yl]-benzonitrile;
6-[(R)-5-(2-{[2-(3-methoxy-phenyl)-pyridin-4-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one;
6-((S)-5-{2-[3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
5-methoxy-3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-2-carbonitrile; and
3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-((S)-5-{2-[3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]thiazin-3-one;
6-((S)-5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-hydroxy-3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
3-[4-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-pyridin-2-yl]-benzonitrile;
2-hydroxy-6-[3-({2-[(R)-2-oxo-3-(3-oxo-3,4-di hydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-isonicotinonitrile;
6-((S)-5-{2-[(3′,4′-dimethoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3-[4-({2-[2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-2,3-dihydro-oxazol-5-yl]-ethylamino}-methyl)-pyridin-2-yl]-benzonitrile;
6-((S)-5-{2-[(3′-cyclobutylmethoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-(5-{2-[3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-[1,3,4]oxadiazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
5-methoxy-3′-({2-[5-oxo-4-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-4,5-dihydro-[1,3,4]oxadiazol-2-yl]-ethylamino}-methyl)-biphenyl-2-carbonitrile;
6-[(S)-5-(2-{[3′-(3-hydroxy-propoxy)-biphenyl-3-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[(S)-5-(2-{[3′-(2-methoxy-ethoxy)-biphenyl-3-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[3-(2-methoxy-pyridin-4-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3′-({2-[5-oxo-4-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-4,5-dihydro-[1,3,4]oxadiazol-2-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-[(S)-5-(2-{3-[6-((RS)-3-hydroxy-pyrrolidin-1-yl)-pyridin-2-yl]-benzylamino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[(3′-cyclopropylmethoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[3-(6-methoxy-pyridazin-4-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
5-[3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridazine-3-carbonitrile;
6-[2-hydroxy-3-({2-[5-oxo-4-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-4,5-dihydro-[1,3,4]oxadiazol-2-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
2-[3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-nicotinonitrile;
6-((S)-5-{2-[(3′-hydroxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[(2′,5′-dimethoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
[3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-yloxy]-acetonitrile;
3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-4-carbonitrile;
6-[(S)-5-(2-{[3′-(4-hydroxy-butoxy)-biphenyl-3-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
[3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-yloxy]-acetic acid ethyl ester;
6-[(S)-5-(2-{3-[6-((3R,4S)-3,4-dihydroxy-cyclopentylmethoxy)-pyridin-2-yl]-benzylamino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[(3′-ethoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
1-[3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-yloxymethyl]-cyclobutanecarbonitrile;
6-[(R)-5-(2-{[5-(3-methoxy-phenyl)-pyridin-3-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one;
3-[3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
6-(5-{2-[2-hydroxy-3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-[1,3,4]oxadiazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3-methoxy-3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-4-carbonitrile;
6-methoxy-3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carboxylic acid methyl ester;
N-methyl-2-[3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-yloxy]-acetamide;
6-((S)-5-{2-[3-(6-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridazine-4-carbonitrile;
6-((S)-5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]oxazin-3-one;
3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-(5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[3-(5-ethoxy-pyridin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-(5-{2-[2-hydroxy-3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3-methoxy-3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-2-carbonitrile;
6-((S)-5-{2-[(6′-methoxy-[2,2]bipyridinyl-4-ylmethyl)-amino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[2-hydroxy-3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
6-((S)-5-{2-[4-hydroxy-3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((S)-5-{2-[2-hydroxy-3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-benzo[1,4]oxazin-3-one;
6-((S)-5-{2-[3-(6-methoxy-pyrazin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[2-hydroxy-3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
6-((S)-5-{2-[2-hydroxy-3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[2-hydroxy-3-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
6-((S)-5-{2-[2-hydroxy-3-(6-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-[2-hydroxy-3-({2-[2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-2,3-dihydro-oxazol-5-yl]-ethylamino}-methyl)-phenyl]-pyridine-2-carbonitrile;
6-((R)-5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((R)-5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-((5)-5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
3′-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-biphenyl-3-carbonitrile;
6-((S)-5-{2-[4-hydroxy-3-(4-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[(S)-5-(2-{[2-(3-methoxy-phenyl)-pyrimidin-4-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[(S)-5-(2-{[5-(3-methoxy-phenyl)-pyridazin-3-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[(S)-5-(2-{[6-(3-methoxy-phenyl)-pyrazin-2-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-[(S)-5-(2-{[6-(3-methoxy-phenyl)-pyridazin-4-ylmethyl]-amino}-ethyl)-2-oxo-oxazolidin-3-yl]-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-((5)-5-{2-[2-hydroxy-3-(4-methoxy-pyridin-2-yl)-benzylamino]-ethyl}-2-oxo-oxazolidin-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-(5-{2-[(3′-methoxy-biphenyl-3-ylmethyl)-amino]-ethyl}-2-oxo-[1,3,4]oxadiazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-(5-{2-[3-(5-methoxy-pyridazin-3-yl)-benzylamino]-ethyl}-2-oxo-[1,3,4]oxadiazol-3-yl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
(S)-6-(5-(2-((4-hydroxy-3-(6-methoxypyridin-2-yl)benzyl)amino)ethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one;
(S)-6-(5-(2-(((5-(5-methoxypyridazin-3-yl)pyridin-3-yl)methyl)amino)ethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or
(S)-6-(5-(2-(((4-(5-methoxypyridazin-3-yl)pyridin-2-yl)methyl)amino)ethyl)-2-oxooxazolidin-3-yl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one;
or a salt of the compound.
11. The compound of formula I according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is formulated as a medicament.
12. A pharmaceutical composition comprising, as active principle, the compound of formula I according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
13. A method of treating a bacterial infection comprising administering to a subject in need thereof the compound, or the salt of the compound according to claim 1 .
14. The method according to claim 13 , wherein the bacterial infection is a respiratory tract infection, otitis media, meningitis, skin and soft tissue infection, pneumonia, bacteremia, endocarditis, intraabdominal infection, gastrointestinal infection, Clostridium difficile infection, urinary tract infection, sexually transmitted infection, foreign body infection, osteomyelitis, Lyme disease, topical infection, opthalmological infection, tuberculosis and tropical diseases.
15. The method according to claim 13 , wherein the compound prevents or treats bacterial infections mediated by Staphylococcus aureus bacteria or Acinetobacter baumannii bacteria.
16. A method of treating a bacterial infection comprising administering to a subject in need thereof the composition according to claim 12 .
17. The method according to claim 16 , wherein the bacterial infection is a respiratory tract infection, otitis media, meningitis, skin and soft tissue infection, pneumonia, bacteremia, endocarditis, intraabdominal infection, gastrointestinal infection, Clostridium difficile infection, urinary tract infection, sexually transmitted infection, foreign body infection, osteomyelitis, Lyme disease, topical infection, opthalmological infection, tuberculosis and tropical disease.
18. The method according to claim 16 , wherein the composition treats bacterial infections mediated by Staphylococcus aureus bacteria or Acinetobacter baumannii bacteria.